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Background: Tamoxifen has dramatically reduced the recurrence and mortality rate of estrogen receptor positive
breast cancer. However, the efficacy of tamoxifen varies between individuals and 40% of patients will have a
recurrence despite adjuvant tamoxifen treatment. Factors that predict tamoxifen efficacy would be helpful for
optimizing treatment. Serum concentrations of the active metabolite, endoxifen, may be positively related to
treatment outcome. In addition, hot flashes are suggested to be positively associated with tamoxifen treatment
outcome.
Methods: We investigated in a series of 109 patients whether the frequency and severity of hot flashes were
related to concentrations of tamoxifen and its metabolites. A serum sample of all patients was analyzed for the
concentration of tamoxifen, N-desmethyltamoxifen, endoxifen and 4-hydroxytamoxifen, as well as for estradiol
concentrations and several single nucleotide polymorphisms in CYP2D6. Additionally, these patients completed a
questionnaire concerning biometric data and treatment side effects.
Results: We found no evidence supporting an association between concentrations of tamoxifen or metabolites and
either the frequency or severity of hot flashes in the covariate unadjusted analyses. However, including interactions
with menopausal status and pre-treatment hot flash (PTHF) history indicated that post-menopausal women with
PTHF experienced an increasing frequency of hot flashes with increasing serum concentrations of tamoxifen and its
metabolites. This finding was not altered when adjusting for potential confounding factors (duration of tamoxifen
treatment, CYP2D6 phenotype, estradiol serum concentration, age and body mass index). In addition we observed
a positive association between body mass index and both hot flash frequency (p = 0.04) and severity (p < 0.0001).
We also observed that patients with lower estradiol levels reported more severe hot flashes (p = 0.02).
Conclusions: No univariate associations were observed between concentrations of active tamoxifen metabolites
and either the frequency or severity of hot flashes during treatment. However, the frequency of hot flashes may be
exacerbated by higher serum concentrations of tamoxifen and its metabolites in post-menopausal women with a
history of hot flashes prior to tamoxifen treatment.
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For over 30 years tamoxifen, a selective estrogen recep-
tor (ER) modulator, has been the standard treatment for
estrogen receptor positive breast cancer patients, in both
the adjuvant and metastatic setting. Tamoxifen has dra-
matically reduced the recurrence and mortality rate for
patients with ER + breast cancer [1]. However, as many
as 40% of patients receiving adjuvant tamoxifen and al-
most all patients with metastatic disease eventually relapse
and die from the disease [2]. Due to this high percentage
of patients with an apparent lack of benefit, identification
of early predictors of outcome of tamoxifen treatment
may be helpful in the optimization of the treatment [3].
Tamoxifen itself is considered to be a prodrug that is
converted into many metabolites. The metabolites with
the highest therapeutic activity are 4-hydroxytamoxifen
and N-desmethyl-4-hydroxytamoxifen (endoxifen), bind-
ing 100-fold more potent to the ER than tamoxifen
itself [4]. The antiestrogenic activities of endoxifen and
4-hydroxytamoxifen are similar, although endoxifen, unlike
4-hydroxytamoxifen, also inhibits aromatase and is present
at higher steady state concentrations in patients than
4-hydroxytamoxifen [4-7]. Recently, Madlensky et al. re-
ported that low endoxifen levels are associated with worse
outcome after tamoxifen treatment, suggesting that there
is a minimum threshold serum level of endoxifen that
when exceeded lowers the recurrence rate [8]. However,
assays for routine measurement of concentrations of tam-
oxifen and its metabolites are not generally available in
daily practice. Therefore, the quest for other biomarkers
for treatment efficacy is still ongoing.
Tamoxifen is metabolized by cytochrome P450 (CYP)
enzymes, in which the formation of endoxifen predom-
inantly depends on CYP2D6. Inactivating genetic poly-
morphisms in CYP2D6 have been associated with lower
endoxifen levels [9-11] and consequently CYP2D6 geno-
type has been suggested as a potentially useful marker
for the prediction of treatment outcome. Recently, the
ATAC and the BIG1-98 studies concluded that genetic
variants of CYP2D6 are not predictive for outcome in
tamoxifen-treated patients [12,13], although the validity
of these findings has been questioned [14].
The occurrence of side effects, such as hot flashes, is a
potential biomarker for treatment outcome, analogous
to what has been described with EGFR inhibitors and
skin-toxicity [15]. It is known that breast cancer patients
treated with tamoxifen suffer more frequently from hot
flashes, compared to placebo-treated breast cancer pa-
tients [16]. The severity of hot flashes is suggested to
increase during the first three months of tamoxifen
treatment, followed by a plateau or even a decrease for
the duration of treatment [17,18].
Mortimer et al. showed that the occurrence of hot
flashes is positively related to outcome after tamoxifentreatment [19]. Cuzick et al. investigated whether the
occurrence of treatment-related symptoms (vasomotor
symptoms or joint symptoms) is associated with breast
cancer recurrence. They found a trend that patients
using tamoxifen who experienced newly emergent vaso-
motor symptoms (e.g. hot flushes, night sweats and cold
sweats) had a lower recurrence rate, although these
results were not statistically significant [20].
Recently, Lorizio et al. reported that the serum concen-
tration of endoxifen is positively associated with the prob-
ability of reporting any side effect from tamoxifen (hot
flashes, vaginal dryness, sleep problems, weight gain, and
depression, irritability or mood swings combining all side
effects and grades). When focusing on hot flashes only,
this association was not statistically significant. Irvin et al.
performed a genotyped tamoxifen dose-escalation study
and found no correlation between endoxifen concentra-
tions and the extent to which patients were bothered by
hot flashes, neither at baseline nor at four months after
dose escalation [10].
In order to clarify whether there is an association be-
tween concentrations of tamoxifen and its main metabo-
lites and either frequency or severity of hot flashes, we
investigated a series of 109 patients treated with tamoxifen,
taking into account potentially influencing factors such as
menopausal status, pre-treatment hot flashes, duration of
tamoxifen treatment, CYP2D6 phenotype, estradiol serum
concentrations, age and body mass index (BMI).
Methods
Patients, both pre- and postmenopausal, who used tam-
oxifen for at least two months at the moment serum
concentrations of tamoxifen and metabolites were deter-
mined as part of routine clinical care were eligible for
this study. Retrospectively, these patients were asked
whether they would be willing to complete a single,
short questionnaire (Additional file 1) concerning bio-
metric data and the side effects they had experienced.
The questionnaire was sent to the patients along with an
informative letter, stating the goal of this study and
explicitly giving the patients the option to opt-out, by
returning the questionnaire without filling it out. By this
questionnaire, patients were asked if they had been ex-
periencing hot flashes prior to beginning tamoxifen
treatment, and also if they experienced hot flashes
during tamoxifen treatment (around the time the blood
sample was drawn). In both cases the patients were
asked to record the frequency of the flashes per week
and the average severity of the experienced hot flashes
(severity categories: mild, <5 minute duration; moderate,
5 to 15 minute duration; severe, 15 to 20 minute dur-
ation; very severe, >20 minute duration). These defini-
tions were based on the methodology and instruments
for conducting hot flash studies [21,22].
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single questionnaire according to the national act on
Ethics Committees (Dutch Act on medical research in-
volving humans, February 26, 1998) and in compliance
with Good Clinical Practice guidelines [23]. As a further
interpretation of these GCP guidelines there is the “code
of conduct of Human Tissue and Medical Research:
Code of conduct for responsible use (2011)” by the
Federa (http://www.federa.org/codes-conduct). In this
code of conduct is stated that anonymous left-over body
material may be used in observational clinical trials
without explicit consent of the individual patients.
Serum sample handling and determination of tamoxifen
and metabolites
The serum samples were collected in serum gel tubes
and stored at −70°C for some weeks, in order to analyze
more patient samples during one HPLC-MS analysis.
Patient samples, calibration standards and quality
control samples were handled according to the method
described by Teunissen et al. [24]. The liquid chroma-
tography – tandem mass spectrometry (LC-MS/MS)
method developed by Teunissen et al. [24] was slightly
modified and used for the determination of tamoxifen
(5 to 500 ng/mL), N-desmethyltamoxifen (10 to 1000 ng/
mL), (E)-endoxifen (1 to 100 ng/mL), (Z)-endoxifen (1 to
100 ng/mL), N-desmethyl-4′-hydroxytamoxifen (1 to
100 ng/mL), 4-hydroxytamoxifen (0.4 to 40 ng/mL) and
4′-hydroxytamoxifen (0.4 to 40 ng/mL). Detection was
performed on a triple-quadrupole MS/MS detector with
an electrospray ionization source (API4000, AB Sciex,
Foster City, USA) operating in the positive ion mode. A
partial validation was executed and all requirements for
acceptance, as defined in the FDA and EMA guidelines on
bioanalytical method validation [25,26] were fulfilled.
Genotyping and predicted phenotype
DNA was isolated from 200 μL serum that was left over
from the tamoxifen and metabolite analysis, using the
MagNA Pure LC Total Nucleic Acid Isolation Kit I and
the automated MagNA PureTM LC system (Roche Diag-
nostics, Mannheim, Germany) according to the manu-
facturer’s manual.
Genotyping was performed according to Standard
Operating Procedures, using assays that were validated
by direct sequencing. In each run, positive and negative
controls were included. All patients were genotyped for
CYP2D6*3, *4, *6 and *41 variant alleles, which will identify
95% of CYP2D6 poor metabolizers (PMs) using Taqman
allelic discrimination assays with primers and probes de-
signed by Applied Biosystems (Carlsbad, California, USA),
as described earlier [27]. Polymerase chain reactions (PCR)
were carried out in a reaction volume of 10 μl, containing
1 ng genomic DNA. The thermal profile consisted of aninitial denaturation step at 95°C for 15 minutes, followed
by 40 cycles of denaturation at 92°C for 15 seconds and
1 minute at 60°C for annealing and extension. Genotypes
were scored through measuring allele-specific fluorescence
using the SDS 2.2.2 software for allelic discrimination
(Applied Biosystems).
On the basis of CYP2D6 genotype patients were classi-
fied into three predicted phenotype groups. Patients
without nonfunctional alleles (CYP2D6*3, *4 or *6) were
defined as extensive metabolizers (EMs). Intermediate
metabolizers (IMs) consisted of patients that (i) carry
CYP2D6*41 alleles either homozygous or in combination
with a nonfunctional allele or (ii) were heterozygous for
the CYP2D6*3, *4, *6 allele (*3/wt, *4/wt or *6/wt). Pa-
tients were classified as PM in case of two nonfunctional
alleles (CYP2D6*3/*3, *3/*4 or *4/*4).
Estradiol concentration
The estradiol concentration was measured in the left
over serum sample on a Modular Analytics E170 im-
munoassay analyzer, using the electrochemiluminescence
technique (Roche Diagnostics), routinely used in the
Netherlands Cancer Institute.
Statistical methods
The relation between hot flashes and several factors was
investigated, where the serum concentrations of tamoxifen
and three of its main metabolites (N-desmethyltamoxifen,
endoxifen and 4-hydroxytamoxifen) were considered of
primary interest. In addition there were seven secondary
factors that may have a potential role confounding role:
menopausal status, a history of hot flashes prior to tamoxi-
fen treatment, duration of tamoxifen treatment, estradiol
serum concentration, age, BMI and CYP2D6 predicted
phenotype. The association between all factors and meno-
pausal status was assessed using Mann–Whitney-Wilcox,
Fisher exact and linear-by-linear tests as appropriate. Spear-
man’s rho was used to assess pairwise covariate associations
between the four primary factors (tamoxifen and metabolite
serum concentrations), age, BMI and estradiol concentra-
tion. Linear by linear trend tests were used to assess the
association between CYP2D6 phenotype and the four
primary factors. Kruskal-Wallis tests was used to determine
if the four factors differed due to menopausal status and
pre-treatment hot flash history. The association between re-
ported hot flash frequency and both primary and secondary
factors was assessed using over-dispersed Poisson models,
both unadjusted (univariable) and multivariable regres-
sions. Similarly, the association between all factors
and the severity of hot flashes was assessed using
proportional-odds ordinal regressions. It was assumed
that these associations may be influenced by meno-
pausal status and the occurrence of pre-tamoxifen treat-
ment hot flashes (PTHF). Due to the small number of
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of menopausal status and PTHF was assessed via pair-
wise interactions with a three level menopausal and
pre-treatment hot flash status variable (pre-menopausal
versus post-menopausal & PTHF versus post-menopausal
& no PTHF). In the multivariable analyses, estradiol con-
centrations were log transformed and missing estradiol
and CYP2D6 values due to insufficient material were im-
puted with population medians. Due to the large number
of individuals missing for the CYP2D6 assessments, sensi-
tivity analyses were performed; once with these individuals
imputed as poor-intermediate metabolizers and once
excluding these individuals. For samples with an estradiol
concentration level below the lower limit of quantitation
(43 pmol/L), half of the lower limit of detection (21.5
pmol/L) was imputed. The level of significance for all tests
was set at 0.05. The analysis was performed using the R
(v3.0.1) using package MASS for ordinal regression and
coin for linear by linear tests (http://cran.r-project.org/).
Results
Cohort
Between July 2008 and December 2011 serum samples
from 165 patients treated with tamoxifen at the
Netherlands Cancer Institute, Amsterdam, the Netherlands
were obtained and analyzed for tamoxifen and metabolite
concentrations. These 165 patients received the question-
naire. 33 patients did not respond to the questionnaire that
was sent and 13 patients returned the reply form empty,
thereby choosing the option to opt-out and not participate
in this study. In total, 119 patients returned a filled out
questionnaire, of which 115 forms were correctly com-
pleted. Six patients were excluded for the following rea-
sons: one patient had an uncertain menopausal status at
the moment of blood sampling; one patient was taking
medication to relieve menopausal complaints; it turned out
that two patients used tamoxifen less than two months at
the moment of blood sampling and two patients used
tamoxifen for distant metastases for an exceptionally long
time (over 6 years). In total, 109 patients (all female, age
mean (range) 51 years (22–76)) were enrolled in the study.
The patients were divided into two groups, based on
menopausal status. Table 1 presents an overview of patient
characteristics.
Table 2 shows that the serum concentrations of tam-
oxifen and its metabolites were not significantly different
between pre- and postmenopausal patients. A total of 92
patients (84%) reported experiencing hot flashes during
tamoxifen treatment, with considerable variation in
reported hot flash severity. Of patients who reported
experiencing no hot flashes before start of tamoxifen
treatment, 65 (79%) reported developing hot flashes dur-
ing treatment whereas all patients who reported experi-
encing hot flashes prior to starting tamoxifen treatmentreported experiencing hot flashes during treatment. The
frequency and severity of the reported hot flashes during
tamoxifen treatment did not differ significantly between
pre- and postmenopausal patients. For two patients, estra-
diol values were missing, due to an insufficient amount of
input material. For 70 (64%) samples the analyzed estra-
diol concentration was below the lower limit of quantifica-
tion (LLOQ, 43 pmol/L).
Genotyping
CYP2D6 genotype predicted phenotype was evaluable
for 89 patients (81.7%). 5 (4.6%) patients were classified
as poor metabolizers (PM), 30 (27.5%) as intermediate
metabolizers (IM) and 54 (49.5%) as extensive metaboli-
zers (EM) (see Table 2). For the other 20 patients (18.3%)
the DNA quality was not sufficient to allow genotyping.
Covariate associations
Spearman’s correlation coefficients indicated a positive
association between tamoxifen and its three main me-
tabolites and a negative association between age and
estradiol levels (see Additional file 2).
In addition, linear by linear tests indicated associations
between CYP2D6 predicted phenotype and endoxifen
(p < 0.0001), N-desmethyltamoxifen (p = 0.009) and
4-hydroxytamoxifen serum concentrations (p = 0.05),
but not tamoxifen concentrations (p = 0.65) (see Additional
file 3). Kruskal-Wallis tests indicated no pairwise associ-
ations between the combined menopausal and PTHF
status variable and tamoxifen nor its three metabolites.
Associations with hot flashes
In the univariable Poisson and ordinal regressions no
associations were found between the levels of tamoxifen,
endoxifen or the two other metabolites and either the
frequency or severity of hot flashes (see Table 3 and
Additional file 4). When including a pairwise interaction
with menopausal and PTHF status it was observed that
the associations between tamoxifen and metabolite serum
concentrations and the frequency of hot flashes were in-
creasing for post-menopausal women with a pre-treatment
history of hot flashes (see Table 3). Adjusting for potential
confounding factors did not alter these results (Additional
file 5; also see Additional file 6 for patient baseline charac-
teristics by menopausal status and PTHF-status). Figure 1
presents the associations between serum concentrations of
tamoxifen and its metabolites and patient-reported hot
flash frequency in the menopausal and PTHF subgroups.
Positive associations were found between BMI and both
hot flash frequency (p = 0.04) and severity (p < 0.0001)
(Table 3A). We also observed that pre-menopausal patients
with lower estradiol levels reported more severe hot flashes
(p = 0.02) (Table 3B). Both of these results remained sig-
nificant in the multivariable analyses (Additional file 5).
Table 1 Patient characteristics
Characteristics Total cohort Pre-menopausal Post-menopausal p-value
n = 109 n = 56 n = 53
n (%) n (%) n (%)
Median age at assessment (years) 51 45 58 <0.0001
Range 22 - 76 22-54 40 - 76
Median Body Mass Index 24 24 24 0.44
Range 17 - 43 17 - 34 18 - 29
T-status (TNM) 0.73
T1 48 (44%) 23 (41%) 25 (47%)
T2 27 (25%) 16 (29%) 11 (21%)
T3 2 (1.8%) 1 (1.8%) 1 (1.9%)
Unknown 32 (29%) 16 (29%) 16 (30%)
N-status (TNM) 1.00
N0 45 (41%) 24 (43%) 21 (40%)
N+ 49 (45%) 26 (46%) 23 (43%)
Unknown 15 (14%) 6 (11%) 9 (17%)
AJCC stage (7th ed.) 0.87
Stage I 26 (24%) 14 (25%) 12 (23%)
Stage IIa 32 (29%) 16 (29%) 16 (30%)
Stage IIb 7 (6%) 5 (9%) 2 (4%)
Stage IIIa 9 (8%) 4 (7%) 5 (9%)
Stage IIIb 0 0 0
Stage IIIc 6 (6%) 3 (5%) 3 (6%)
Unknown 29 (27%) 14 (25%) 15 (28%)
Estrogen receptor NA
Positive 93 (85%) 50 (89%) 43 (81%)
Unknown 16 (15%) 6 (11%) 10 (19%)
Progesterone receptor 1.00
Positive 10 (9%) 5 (9%) 5 (9%)
Negative 83 (76%) 45 (80%) 38 (72%)
Unknown 16 (15%) 6 (11%) 10 (19%)
HER2 status 1.00
Positive 38 (35%) 20 (36%) 18 (34%)
Negative 55 (50%) 30 (54%) 25 (47%)
Unknown 16 (15%) 6 (11%) 10 (19%)
Median duration of treatment (months) 9 9 9 0.73
Range 2 - 70 2 - 59 3 - 70
Tamoxifen (daily dose) 0.17
10 mg 1 (1%) 1 (2%) 0 (0%)
20 mg 102 (94%) 50 (89%) 52 (98%)
40 mg 6 (6%) 5 (9%) 1 (2%)
T-status, Tumor status, N-status, Lymph node status, HER2, Human Epidermal growth factor Receptor 2.
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coefficients were unaffected by the imputation of the
missing CYP2D6 levels. While the tests for interactionremained significant when the missing data were im-
puted (both as poor-intermediate and as extensive
metabolizers), these tests were non-significant in the
Table 2 Hot flash frequency and severity and pharmacological and biochemical parameters of study participants
during treatment with tamoxifen
Total Pre-menopausal Post-menopausal p-value
n = 109 n = 56 n = 53
n (%) n (%) n (%)
Pre-treatment history of hot flashes 0.04
No 82 (75%) 47 (84%) 35 (66%)
Yes 27 (25%) 9 (16%) 18 (34%)
Median frequency of hot flashes per week 21 21 21 0.77
Range 0 - 168 0 - 168 0 - 168
Average severity of hot flashes 0.56
None 17 (16%) 9 (16%) 8 (15%)
Mild 22 (20%) 13 (23%) 9 (17%)
Moderate 55 (50%) 26 (46%) 29 (55%)
Severe 11 (10%) 7 (12%) 4 (8%)
Very severe 4 (4%) 1 (2%) 3 (6%)
Median tamoxifen (ng/mL) 95.4 93.8 97.9 0.61
Range 39.7 - 237 50.0 - 220 39.7 - 237
Median N-desmethyltamoxifen (ng/mL) 181 177 187 0.82
Range 82.3 - 532 94.3 - 532 82.3 - 439
Median endoxifen (ng/mL) 9.12 8.59 9.16 0.75
Range 1.73 – 22.6 1.73 – 20.3 2.14 – 22.6
Median 4-hydroxytamoxifen (ng/mL) 1.69 1.77 1.43 0.91
Range 0.74 - 4.23 0.74 - 4.23 0.78 - 3.51
Median estradiol (pmol/L) 0.06
<LLOQ* 70 33 37
43.0 – 67.0 12 6 6
67.0 – 361 14 8 6
>361 11 9 2
Missing 2 0 2
CYP2D6 phenotype 0.66
Extensive metabolizer 54 (50%) 28 (50%) 26 (49%)
Intermediate metabolizer 30 (28%) 19 (34%) 11 (21%)
Poor metabolizer 5 (5%) 2 (4%) 3 (6%)
Missing 20 (18%) 7 (12%) 13 (24%)
*<LLOQ is below the minimal quantification limit.
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18% reduction in sample size.
CYP2D6 predicted phenotype was not associated with
hot flash frequency (p = 0.61) nor hot flash severity
(p = 0.99) (Table 3).
Discussion
In this study we were unable to find evidence supporting
the hypothesis that either frequency or severity of hot
flashes are associated with higher levels of tamoxifen or
any of its main metabolites during treatment in our en-
tire cohort, consisting of both pre- and postmenopausalpatients. No differences were detected in the frequency
of reported hot flashes between pre- and post-menopausal
women, however the association between concentrations
of tamoxifen and its metabolites and patient-reported hot
flash frequency appeared to be influenced by menopausal
status and pre-treatment hot flash history.
Previously, Lorizio et al. have suggested that the
endoxifen serum concentration was associated with in-
creased risk of hot flashes, although this finding was not
statistically significant [28]. Irvin et al. found no associ-
ation between the extent to which patients were both-
ered by hot flashes and endoxifen concentration, neither
Table 3 Univariable Poisson regression associations with hot flash frequency (3A) and ordinal regression associations
with hot flash severity (3B)
3A Univariable (N = 109) Inter. Pre-M. (N = 56) Post-M & PTHF
(N = 18)
Post-M & no PTHF
(N = 35)
Coef SE p-value p-value Coef SE p-value Coef SE p-value Coef SE p-value
Tamoxifen 0.002 0.0024 0.41 0.03 −0.0045 0.004 0.27 0.012 0.0038 0.01 0.0058 0.0044 0.19
N-desmethyltamoxifen −0.00002 0.0013 0.99 0.13 −0.0013 0.002 0.50 0.0053 0.002 0.02 −0.0014 0.0031 0.66
Endoxifen −0.015 0.022 0.50 0.01 −0.069 0.03 0.03 0.085 0.028 0.01 −0.0021 0.05 0.97
4-Hydroxytamoxifen −0.05 0.14 0.73 0.03 −0.3 0.19 0.13 0.63 0.17 0.002 −0.056 0.37 0.88
Post-M & PTHF v pre-M 0.13 0.27 0.67
Post-M & no PTHF v
pre-M
−0.14 0.24
Age −0.0059 0.0098 0.55
Estradiol concentration −0.12 0.095 0.21
BMI 0.048 0.023 0.04
Tamoxifen duration 0.084 0.087 0.34
CYP2D6: EM versus I/PM −0.11 0.21 0.61
3B Univariable (N = 109) Inter. Pre-M. (N = 56) Post-M & PTHF
(N = 18)
Post-M & no PTHF
(N = 35)
Coef SE p-value p-value Coef SE p-value Coef SE p-value Coef SE p-value
Tamoxifen 0.0026 0.0045 0.57 0.60 0.0026 0.0065 0.69 0.018 0.014 0.16 0.0019 0.0075 0.80
N-desmethyltamoxifen −0.00043 0.0022 0.85 0.30 −0.00048 0.003 0.88 0.01 0.0067 0.11 −0.0024 0.0039 0.53
Endoxifen −0.013 0.039 0.73 0.72 −0.027 0.055 0.62 0.044 0.092 0.63 0.025 0.072 0.73
4-Hydroxytamoxifen −0.20 0.25 0.43 0.64 −0.11 0.31 0.74 0.39 0.70 0.58 −0.36 0.52 0.48
Post-M & PTHF v pre-M 0.94 0.51 0.11
Post-M & no PTHF v
pre-M
−0.17 0.42
Age −0.018 0.017 0.31
Estradiol concentration −0.34 0.14 0.02
BMI 0.19 0.048 <0.0001
Tamoxifen duration 0.25 0.18 0.15
CYP2D6: EM versus I/PM 0.0058 0.41 0.99
Inter, Interaction; pre-M, Pre-menopausal patients; post-M, Post-menopausal patients; PTHF, Pre-treatment hot flashes; v, Versus; Coef, Coefficient; SE, Standard
error; BMI, Body mass index; EM, Extensive metabolizers; I/PM, Intermediate to poor metabolizers.
For tamoxifen and its metabolites the test of interaction with menopausal and PTHF status, and the within-group associations are also reported.
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[10]. We initiated this study to investigate the associ-
ation of concentrations of tamoxifen and its main me-
tabolites and both severity and frequency of hot flashes,
taking potential confounding factors, such as meno-
pausal status, pre-treatment hot flash history, duration
of tamoxifen treatment, CYP2D6 phenotype, estradiol
levels, age and BMI, into account. We could, however,
find no evidence to support this hypothesis in the whole
cohort. In the earlier mentioned BIG1-98 study, the
authors also investigated hot flash incidence and the
aggravation of hot flashes in the first two years of tam-
oxifen therapy. They found an association between
CYP2D6 phenotype and tamoxifen-induced hot flashes
(p = 0.02): both PM and IM phenotypes had an in-
creased risk of tamoxifen-induced hot flashes comparedwith EM phenotype [13], contradictory to what was ex-
pected. Additionally, Sestak et al. [29] and Goetz et al.
[30] reported that they were unable to detect an associ-
ation between CYP2D6 phenotype and the occurrence
of hot flashes. In this study we also found no evidence
supporting the hypothesis that either hot flash fre-
quency or severity is associated with CYP2D6 predicted
phenotype, however genotyping data was missing in
18% of the cases. The large percentage of genotyping
failures can be explained by the fact that DNA was iso-
lated from serum, since this matrix was left over from
the tamoxifen and metabolite analysis, which is a repro-
ducible and validated method for genotyping in our lab,
however the yield is low. Although the physiology of hot
flashes, in both healthy women and women with breast
cancer, remains unclear, it has been observed that
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Figure 1 Hot-flash frequency plotted against tamoxifen and its metabolites, for pre- and post-menopausal women separately.
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flashes have lower estradiol levels than women who do
not experience hot flashes [31-34]. In our series, we
correspondingly observed that patients, especially
pre-menopausal patients, with lower estradiol levels
reported more severe hot flashes.
Another physiological factor that may influence the
occurrence of hot flashes in healthy women is body mass
index (BMI), although this relationship is still a matter
of debate. Some studies found a positive association [35],
others a negative association [36,37] or no association
[38]. In our series patients with higher BMIs reported
suffering from more frequent and severe hot flashes.
Tamoxifen is metabolized into many different metabo-
lites by cytochrome P450, the formation of endoxifen is
mainly dependent on CYP2D6 activity. As with other
studies [9-11], we were able to demonstrate a positive
association between CYP2D6 activity and serum concen-
trations of active tamoxifen metabolites.
Our study has the following limitations. The hot flash
data was collected retrospectively. Consequently, we are
unable to completely exclude recall-bias concerning thegrade and frequency of the hot flashes. Also, the modest
sample size of this retrospective study requires that these
results should be interpreted with care. Furthermore, only
a single questionnaire was completed per patient, and as
such we are unable to identify fluctuations in frequency
and severity of hot flashes over the course of the tamoxifen
treatment period. To adjust for any potential confounding,
the duration of tamoxifen treatment was included as a co-
variate in the analyses. Finally, we have insufficient data
concerning co-medication, other than medication to re-
lieve hot flashes, to include this factor in our analyses,
however, in the ATAC analyses medication use was not
found to be an independent predictor [12].
This is the first study reporting a difference within
post-menopausal patients based on their pre-treatment
hot flash history in the association between tamoxifen
and its main metabolite serum concentrations and hot
flash frequency. This possible effect should be investi-
gated further and requires validation in other series.
As we are unable to show that hot flash assessments
are unambiguously indicative for therapeutic serum con-
centrations of endoxifen, and given that the value of
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http://www.biomedcentral.com/1471-2407/13/612pharmacogenomics is currently under debate, we think
that future research could focus on measurement of
active metabolite concentrations as a potential surrogate
biomarker for tamoxifen efficacy.
Conclusions
We are unable to confirm positive associations between
active tamoxifen metabolite concentrations and either
the frequency or severity of hot flashes during tamoxifen
treatment, when ignoring menopausal status and pre-
treatment hot flash history. However, within the post-
menopausal women experiencing hot flashes prior to
treatment, there is evidence for positive associations be-
tween serum concentrations of tamoxifen and its metab-
olites with hot flash frequency.
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